Overview

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid Metabolic Syndrome (METSYN).

Phase:

Phase 2

Details

Lead Sponsor:

Joseph Calabrese, MD

Collaborator:

Takeda Pharmaceuticals North America, Inc.

Treatments:

Pioglitazone